Jun 15
2022
Phanes Therapeutics announces FDA IND clearance for PT886, an anti-claudin18.2/anti-CD47 bispecific antibody being developed for patients with gastric, gastroesophageal junction, and pancreatic cancers
SAN DIEGO, June 15, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical...
Read More
Apr 21
2022
Phanes Therapeutics revealed manufacturing validation of its bispecific technology platforms PACbody™ and SPECpair™ at AACR 2022
SAN DIEGO, April 20, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology,...
Read More
Apr 13
2022
Phanes Therapeutics’ anti-CD73 antibody patent granted in the US
SAN DIEGO, April 12, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology,...
Read More
Mar 23
2022
Phanes Therapeutics announces FDA IND clearance for PT199, a next generation monoclonal antibody against human CD73
SAN DIEGO, March 22, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in immuno-oncology...
Read More
Mar 17
2022
Phanes Therapeutics Announces Three Upcoming Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting
SAN DIEGO, March 16, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology,...
Read More
Feb 8
2022
Phanes Therapeutics’ antibody patent granted
SAN DIEGO, Feb. 4, 2022 Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology announced...
Read More
Jan 12
2022
Phanes Therapeutics announces the appointment of Vice President of Business Development
SAN DIEGO, Jan. 11, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that...
Read More
Dec 16
2021
PHANES THERAPEUTICS TO PRESENT AT BIOTECH SHOWCASE™ 2022 IN SAN FRANCISCO – Company expects to file three INDs in 2022
SAN DIEGO, Dec. 15, 2021 /PRNewswire/ -- Phanes Therapeutics, Inc., an emerging biotech company focused on innovative drug discovery and development in...
Read More
Sep 13
2021
Phanes Therapeutics reveals SPECpair™ technology platform that enhances manufacturability of bispecific antibodies
SAN DIEGO, Sept. 10, 2021 Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative drug discovery research and development in immuno-oncology...
Read More
May 25
2021
Phanes Therapeutics Announces $40 million Series B Financing
SAN DIEGO and SHANGHAI, May 25, 2021 Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative drug discovery in immuno-oncology,...
Read More
